Please login to the form below

Not currently logged in
Email:
Password:

AZ integrates Cambridge Antibody Technology into MedImmune

AstraZeneca integrates Cambridge Antibody Technology into its global biologics business under the MedImmune banner

Anglo-Swedish pharmaceutical company AstraZeneca (AZ) has integrated UK-based biopharmaceutical company Cambridge Antibody Technology (CAT) into its global biologics business under the MedImmune banner.

The new business unit will unite the resources and expertise from CAT, MedImmune and other biologics activities within AZ.

With the revised structure, AZ has created a biotech with total revenues of over USD 1.3bn FY06, a pipeline of approximately 100 research projects and more than 12 clinical product candidates. The new entity also employs 3,000 people worldwide.

As part of the integration, Dr John Stageman, vice-president of AZ's biopharmaceutical strategic planning, will act as interim head of the UK Cambridge site.

AZ purchased CAT in June 2006 in order to boost by 25 per cent the number of biologics in its product pipeline by 2010. The company acquired MedImmune in 2007.

David M Mott, MedImmune's CEO, said: "The new MedImmune is now the operationally independent and strategically aligned biologics business unit of AZ. Bringing together the biologics expertise of CAT, MedImmune and AZ allows us to preserve MedImmune's traditional biotech agility and entrepreneurial spirit while encouraging strategic collaboration and cross fertilization of ideas under AZ's world-class research umbrella."

Dr Stageman added: "AZ's biologics capabilities have been enhanced significantly by the acquisitions of CAT and MedImmune to create a more robust, highly competitive and fully integrated biotechnology business. The scientific, technical and medical expertise that this team brings together is world class in discovering, developing, manufacturing and commercialising biopharmaceutical products."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics